Identification of a Druggable Pathway Controlling Glioblastoma Invasiveness.

Cell Rep

Division of Molecular Carcinogenesis and Cancer Genomics Center Netherlands, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands. Electronic address:

Published: July 2017


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Diffuse and uncontrollable brain invasion is a hallmark of glioblastoma (GBM), but its mechanism is understood poorly. We developed a 3D ex vivo organotypic model to study GBM invasion. We demonstrate that invading GBM cells upregulate a network of extracellular matrix (ECM) components, including multiple collagens, whose expression correlates strongly with grade and clinical outcome. We identify interferon regulatory factor 3 (IRF3) as a transcriptional repressor of ECM factors and show that IRF3 acts as a suppressor of GBM invasion. Therapeutic activation of IRF3 by inhibiting casein kinase 2 (CK2)-a negative regulator of IRF3-downregulated the expression of ECM factors and suppressed GBM invasion in ex vivo and in vivo models across a panel of patient-derived GBM cell lines representative of the main molecular GBM subtypes. Our data provide mechanistic insight into the invasive capacity of GBM tumors and identify a potential therapy to inhibit GBM invasion.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.06.036DOI Listing

Publication Analysis

Top Keywords

gbm invasion
16
gbm
9
ecm factors
8
invasion
5
identification druggable
4
druggable pathway
4
pathway controlling
4
controlling glioblastoma
4
glioblastoma invasiveness
4
invasiveness diffuse
4

Similar Publications

HIC2 Suppresses Glioblastoma Progression via Transcriptional Repression of SEMA3A and Inhibition of TGF-β Signaling.

Free Radic Biol Med

September 2025

Department of Neurosurgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. Electronic address:

Glioblastoma (GBM), the most aggressive primary brain tumor, is associated with dismal clinical outcomes and a critical lack of actionable therapeutic targets. Herein, we report that Hypermethylated in Cancer 2 (HIC2) is significantly downregulated in GBM tissues. In vitro, ectopic overexpression of HIC2 markedly suppresses GBM cell proliferation, invasion, and migration, while in vivo, it substantially inhibits tumor growth and prolongs survival in an orthotopic xenograft model (p < 0.

View Article and Find Full Text PDF

The prognosis of glioblastoma multiforme (GBM) remains dismal, despite standard treatment regimens. A key challenge in treating GBM is the persistence of glioma stem cells (GSCs) within the perivascular niche (PVN) - a protective tumor microenvironment (TME) that is often associated with inadequate drug penetration. Current preclinical models do not capture complexity of the human TME, particularly the vasculature and niche-specific interactions that drive GBM progression.

View Article and Find Full Text PDF

Glioblastoma multiforme (GBM) is a rapidly progressing brain malignancy, with its progression closely tied to a hypoxic microenvironment. Hypoxia-inducible factor-1α (HIF-1α) acts as a vital regulator in tumor adaptation to low oxygen levels, and its relationship with the Wnt/β-catenin signaling pathway exerts significant functions in the malignant properties of GBM. In this research, Western blot and qRT-PCR were applied to check β-catenin and HIF-1α expression in GBM.

View Article and Find Full Text PDF

Introduction: Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with a poor prognosis, primarily due to therapy resistance mediated by CD133+ glioblastoma stem cells (GSCs). The BCL3 gene contributes to this resistance and is potentially regulated by Carbonic Anhydrase II (CA II). Additionally, BCL3 enhances β-catenin-mediated transcription, promoting tumor growth.

View Article and Find Full Text PDF

Background: Papillary thyroid carcinoma (PTC) frequently develops lateral lymph node metastasis (LLNM) in 12.6%-32.8% of patients, increasing recurrence risk and mortality.

View Article and Find Full Text PDF